Status:
NOT_YET_RECRUITING
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
Lead Sponsor:
British Columbia Cancer Agency
Conditions:
Breast Cancer
Metastases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer. Secondary objectives will be overall survival, ...
Detailed Description
Purpose: The purpose of this study is to determine if stereotactic ablative radiotherapy (SABR) can provide effective locoregional control for patients with metastatic breast cancer. As secondary obj...
Eligibility Criteria
Inclusion
- Pathologically confirmed AJCC 7th/8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.
- Measurable disease in the breast, suitable to receive radiotherapy.
- Receiving or planned to receive systemic therapy.
- a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4/6 inhibitors, T-DXd
- Patients are allowed to have SABR for oligometastatic disease as clinically indicated
- Age 18 or older
- ECOG Performance Status 0-2
- Life expectancy greater than 6 months
- Able and willing to provide informed consent
- Able to complete patient reported outcome questionnaires
Exclusion
- Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy
- Previous history of locoregional radiotherapy to the ipsilateral breast
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2030
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06937281
Start Date
July 1 2025
End Date
July 30 2030
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6